Tagged with ess

Mexico The lowest spender on healthcare as a percentage of GDP in mainland Latin America. A complex and fragmented reimbursement system. Clinical trial approval delays stretching across eight months. One could be forgiven for thinking that attempting to bring innovative medicines to Mexico is a thankless task. Yet, as several country…

Switzerland Dr René Buholzer, CEO of Interpharma, covers Switzerland’s healthcare advancements, regulatory progress, and the challenges in drug access and digitalization over the past three years. Emphasising collaboration and innovation, Interpharma’s ‘Pharma Strategy 2030’ aims to solidify Switzerland’s leadership in R&D and healthcare sustainability.   Our vision is not just about…

Switzerland The Federal Office of Public Health (FOPH) is the body responsible for safeguarding public health in Switzerland, developing national health policies, and overseeing the Swiss healthcare system. In an exclusive conversation, FOPH Director Anne Lévy discusses the key challenges facing the Swiss healthcare system today and highlights potential solutions as…

Switzerland Thomas Wirth shares insights into Biomed’s strategic focus on the Swiss pharmaceutical market, offering comprehensive services from regulatory support to market access for RX and OTC products. He discusses Biomed’s commitment to long-term partnerships, technological advancements, and driving operational efficiency to stay competitive.   At Biomed, we prioritize delivering value…

Switzerland Katharina Gasser of Roche Pharma Switzerland lays out her dedication to fostering innovation, strengthening team dynamics, and influencing the future of Switzerland’s healthcare landscape. Gasser emphasizes the need to combat complacency, advance digitalization, and promote diversity in leadership, noting that “complacency is a real threat—it stifles innovation, diminishes drive, and…

Global The global pharma industry is facing increased pressure to ensure lifesaving medications reach underserved populations. Drawing from a new Access to Medicine Foundation report, AMF Head of Research Claudia Martinez shares some exclusive insights on where pharma has made significant strides on the important metric of ‘patient reach’ and the…

Switzerland Lucas Schalch of Intergenerika examines the challenges confronting Switzerland’s generic and biosimilar sectors, such as high production costs and changing regulations. Schalch underscores the importance of maintaining a favourable economic environment for these industries.   We must work together to sustain a healthy and competitive market, ensuring that the generic…

Global The timely and equitable provision of treatment and prevention tools is just one part of the ongoing fight against HIV. Local, national, regional, and international authorities – many of which still labour under misguided preconceptions about people living with HIV – need to come together to effectively buttress the provision…

Mexico FUNSALUD is a leading Mexican think tank focused on improving public health through research, advocacy, and promoting public-private partnerships. As Mexico prepares to welcome a new president, FUNSALUD’s Hector Valle casts his eye over the evolving healthcare landscape in terms of both progress made in addressing access gaps and how…

Global In 2024, people living with HIV have more, and more varied, access to HIV prevention and treatment options than ever before. Thanks to global activism efforts forcing pharma to step up, and the establishment of some vital institutional structures in the first decade of the millennium, access is up, while…

Africa Leading HIV patient advocate Flavia Kyomukama talks through the evolution of access to HIV treatment and prevention in Uganda over the last 30 years, as well as the challenges that remain, including sustaining the HIV response, combating stigma, and ensuring the prevention of mother-to-child transmission. She touches on some of…

Global Speaking to PharmaBoardroom in the context of our upcoming InFocus special report on HIV, Access to Medicine Foundation CEO Jayasree Iyer looks back on pharma’s successes and failures in access to HIV treatment and prevention. Iyer highlights the impact of voluntary licensing of drugs via the Medicines Patent Pool and…